158 related articles for article (PubMed ID: 38676807)
21. Application of patient-derived liver cancer cells for phenotypic characterization and therapeutic target identification.
Castven D; Becker D; Czauderna C; Wilhelm D; Andersen JB; Strand S; Hartmann M; Heilmann-Heimbach S; Roth W; Hartmann N; Straub BK; Mahn FL; Franck S; Pereira S; Haupts A; Vogel A; Wörns MA; Weinmann A; Heinrich S; Lang H; Thorgeirsson SS; Galle PR; Marquardt JU
Int J Cancer; 2019 Jun; 144(11):2782-2794. PubMed ID: 30485423
[TBL] [Abstract][Full Text] [Related]
22. Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design.
Rokita JL; Rathi KS; Cardenas MF; Upton KA; Jayaseelan J; Cross KL; Pfeil J; Egolf LE; Way GP; Farrel A; Kendsersky NM; Patel K; Gaonkar KS; Modi A; Berko ER; Lopez G; Vaksman Z; Mayoh C; Nance J; McCoy K; Haber M; Evans K; McCalmont H; Bendak K; Böhm JW; Marshall GM; Tyrrell V; Kalletla K; Braun FK; Qi L; Du Y; Zhang H; Lindsay HB; Zhao S; Shu J; Baxter P; Morton C; Kurmashev D; Zheng S; Chen Y; Bowen J; Bryan AC; Leraas KM; Coppens SE; Doddapaneni H; Momin Z; Zhang W; Sacks GI; Hart LS; Krytska K; Mosse YP; Gatto GJ; Sanchez Y; Greene CS; Diskin SJ; Vaske OM; Haussler D; Gastier-Foster JM; Kolb EA; Gorlick R; Li XN; Reynolds CP; Kurmasheva RT; Houghton PJ; Smith MA; Lock RB; Raman P; Wheeler DA; Maris JM
Cell Rep; 2019 Nov; 29(6):1675-1689.e9. PubMed ID: 31693904
[TBL] [Abstract][Full Text] [Related]
23. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model.
Daher A; de Groot J
Exp Neurol; 2018 Jan; 299(Pt B):281-288. PubMed ID: 28923369
[TBL] [Abstract][Full Text] [Related]
24. Tegavivint and the β-Catenin/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma.
Nomura M; Rainusso N; Lee YC; Dawson B; Coarfa C; Han R; Larson JL; Shuck R; Kurenbekova L; Yustein JT
J Natl Cancer Inst; 2019 Nov; 111(11):1216-1227. PubMed ID: 30793158
[TBL] [Abstract][Full Text] [Related]
25. Advances in phosphoproteomics and its application to COPD.
Zeng X; Lan Y; Xiao J; Hu L; Tan L; Liang M; Wang X; Lu S; Peng T; Long F
Expert Rev Proteomics; 2022; 19(7-12):311-324. PubMed ID: 36730079
[TBL] [Abstract][Full Text] [Related]
26. Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine.
Rivera M; Fichtner I; Wulf-Goldenberg A; Sers C; Merk J; Patone G; Alp KM; Kanashova T; Mertins P; Hoffmann J; Stein U; Walther W
Neoplasia; 2021 Jan; 23(1):21-35. PubMed ID: 33212364
[TBL] [Abstract][Full Text] [Related]
27. Identification of novel signaling components in N,N'-dinitrosopiperazine-mediated metastasis of nasopharyngeal carcinoma by quantitative phosphoproteomics.
Huang D; Li Y; Liu N; Zhang Z; Peng Z; Duan C; Tang X; Tan G; Yan G; Tang F
BMC Cancer; 2014 Apr; 14():243. PubMed ID: 24708550
[TBL] [Abstract][Full Text] [Related]
28. Recent Advances of Functional Proteomics in Gastrointestinal Cancers- a Path towards the Identification of Candidate Diagnostic, Prognostic, and Therapeutic Molecular Biomarkers.
Abyadeh M; Meyfour A; Gupta V; Zabet Moghaddam M; Fitzhenry MJ; Shahbazian S; Hosseini Salekdeh G; Mirzaei M
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33198323
[TBL] [Abstract][Full Text] [Related]
29. Novel patient-derived xenograft and cell line models for therapeutic testing of pediatric liver cancer.
Bissig-Choisat B; Kettlun-Leyton C; Legras XD; Zorman B; Barzi M; Chen LL; Amin MD; Huang YH; Pautler RG; Hampton OA; Prakash MM; Yang D; Borowiak M; Muzny D; Doddapaneni HV; Hu J; Shi Y; Gaber MW; Hicks MJ; Thompson PA; Lu Y; Mills GB; Finegold M; Goss JA; Parsons DW; Vasudevan SA; Sumazin P; López-Terrada D; Bissig KD
J Hepatol; 2016 Aug; 65(2):325-33. PubMed ID: 27117591
[TBL] [Abstract][Full Text] [Related]
30. Identification of kinase inhibitor targets in the lung cancer microenvironment by chemical and phosphoproteomics.
Gridling M; Ficarro SB; Breitwieser FP; Song L; Parapatics K; Colinge J; Haura EB; Marto JA; Superti-Furga G; Bennett KL; Rix U
Mol Cancer Ther; 2014 Nov; 13(11):2751-62. PubMed ID: 25189542
[TBL] [Abstract][Full Text] [Related]
31. Systems Analysis for Interpretation of Phosphoproteomics Data.
Munk S; Refsgaard JC; Olsen JV
Methods Mol Biol; 2016; 1355():341-60. PubMed ID: 26584937
[TBL] [Abstract][Full Text] [Related]
32. Patient-derived xenograft: a developing tool for screening biomarkers and potential therapeutic targets for human esophageal cancers.
Lan T; Xue X; Dunmall LC; Miao J; Wang Y
Aging (Albany NY); 2021 Apr; 13(8):12273-12293. PubMed ID: 33903283
[TBL] [Abstract][Full Text] [Related]
33. Identification of Therapeutic Targets in Rhabdomyosarcoma through Integrated Genomic, Epigenomic, and Proteomic Analyses.
Stewart E; McEvoy J; Wang H; Chen X; Honnell V; Ocarz M; Gordon B; Dapper J; Blankenship K; Yang Y; Li Y; Shaw TI; Cho JH; Wang X; Xu B; Gupta P; Fan Y; Liu Y; Rusch M; Griffiths L; Jeon J; Freeman BB; Clay MR; Pappo A; Easton J; Shurtleff S; Shelat A; Zhou X; Boggs K; Mulder H; Yergeau D; Bahrami A; Mardis ER; Wilson RK; Zhang J; Peng J; Downing JR; Dyer MA;
Cancer Cell; 2018 Sep; 34(3):411-426.e19. PubMed ID: 30146332
[TBL] [Abstract][Full Text] [Related]
34. PLK2 modulation of enriched TAp73 affects osteogenic differentiation and prognosis in human osteosarcoma.
Li W; Zhang X; Xi X; Li Y; Quan H; Liu S; Wu L; Wu P; Lan W; Shao Y; Li H; Chen K; Hu Z
Cancer Med; 2020 Jun; 9(12):4371-4385. PubMed ID: 32349184
[TBL] [Abstract][Full Text] [Related]
35. Integrated proteomic and phosphoproteomic analysis for characterization of colorectal cancer.
Zhu H; Li Y; Guo J; Feng S; Ge H; Gu C; Wang M; Nie R; Li N; Wang Y; Wang H; Zhong J; Qian X; He G
J Proteomics; 2023 Mar; 274():104808. PubMed ID: 36596410
[TBL] [Abstract][Full Text] [Related]
36. Proteomics discovery of radioresistant cancer biomarkers for radiotherapy.
Chang L; Graham P; Hao J; Bucci J; Malouf D; Gillatt D; Li Y
Cancer Lett; 2015 Dec; 369(2):289-97. PubMed ID: 26427840
[TBL] [Abstract][Full Text] [Related]
37. Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models.
Vangala D; Ladigan S; Liffers ST; Noseir S; Maghnouj A; Götze TM; Verdoodt B; Klein-Scory S; Godfrey L; Zowada MK; Huerta M; Edelstein DL; de Villarreal JM; Marqués M; Kumbrink J; Jung A; Schiergens T; Werner J; Heinemann V; Stintzing S; Lindoerfer D; Mansmann U; Pohl M; Teschendorf C; Bernhardt C; Wolters H; Stern J; Usta S; Viebahn R; Admard J; Casadei N; Fröhling S; Ball CR; Siveke JT; Glimm H; Tannapfel A; Schmiegel W; Hahn SA
Genome Med; 2021 Jul; 13(1):116. PubMed ID: 34271981
[TBL] [Abstract][Full Text] [Related]
38. Patient-Derived Xenografts: A Valuable Preclinical Model for Drug Development and Biomarker Discovery.
Weng T; Jenkins BJ; Saad MI
Methods Mol Biol; 2024; 2806():19-30. PubMed ID: 38676793
[TBL] [Abstract][Full Text] [Related]
39. Long non-coding RNA XIST promotes osteosarcoma progression by targeting YAP via miR-195-5p.
Yang C; Wu K; Wang S; Wei G
J Cell Biochem; 2018 Jul; 119(7):5646-5656. PubMed ID: 29384226
[TBL] [Abstract][Full Text] [Related]
40. Phosphoproteomics-Based Profiling of Kinase Activities in Cancer Cells.
Wirbel J; Cutillas P; Saez-Rodriguez J
Methods Mol Biol; 2018; 1711():103-132. PubMed ID: 29344887
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
